Company news

ACADIA Pharmaceuticals Inc. news in 2024

ACADIA Pharmaceuticals Inc.'s news releases, calls and decks from 2024, newest first.

View company

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

December 18, 2024

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

December 10, 2024

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

December 8, 2024

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

November 25, 2024

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

November 5, 2024

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

November 4, 2024

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

October 16, 2024

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome

October 15, 2024

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

September 22, 2024

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference

August 6, 2024

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

August 5, 2024

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024

July 23, 2024

Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med

July 17, 2024

Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting

June 17, 2024

Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome

May 14, 2024

Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview

May 7, 2024

Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship

April 28, 2024

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024

April 23, 2024

Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

April 21, 2024

Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting

April 16, 2024

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

April 1, 2024

Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 31, 2024

Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day

March 12, 2024

Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia

March 10, 2024

Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024

February 28, 2024

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview

February 26, 2024

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

February 12, 2024

Acadia Announces Additions to Executive Team

January 29, 2024

Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic

January 17, 2024

Calls in 2024

Decks in 2024